H3 Biomedicine, Selvita expand precision cancer medicine alliance

The druggability of two kinase targets in a specific genetic context is being validated by the two companies as part of the original alliance started in September 2013.

Several novel chemical series have been generated against the targets. The companies plan to make further progress for starting IND enabling studies in next year.

The companies will present the results from both programs at scientific conferences in the first half of next year.

Selvita CEO Pawel Przewiezlikowski said: "Since the start of our collaboration, our teams have worked very well together, complementing each other’s efforts.

"The results of both programs have been very promising and we look forward to seeing our jointly discovered molecules progressing through further studies."

H3 Biomedicine president and CEO Markus Warmuth said: "Together we have continued to validate targets within a specific genomic context, which is at the core of H3’s vision and mission.

"The strength of the combined teams has allowed for rapid advancement of the biology and chemistry in parallel. We look forward to further advancing the programs from discovery to translation over the next year."

Earlier this year, H3 Biomedicine partnered with Foundation Medicine to discover and develop precision medicines in oncology.

H3 has developed four discovery platforms, which have produced two drug candidates for which the company anticipates to submit investigational new drug applications later this year.